Tioga Cardiovascular develops a next-generation transseptal mitral valve replacement (TMVR) technology and is focused on mitral and tricuspid transcatheter valve solutions. The company is a privately held portfolio company of Shifamed LLC and is based in Los Gatos, Calif. Its TMVR approach emphasizes a smaller delivery system, transseptal delivery, reduced left ventricular outflow tract (LVOT) obstruction, and procedural simplicity. Tioga positions its device as a less invasive option intended to address unmet clinical needs in patients with severe mitral regurgitation. The company will use recent financing to continue product development, support pre-clinical testing, and initiate first-in-human use. Tioga highlights the large addressable market for mitral valve disease, noting it affects millions and is often undertreated due to surgical risks. Tioga Medical is a Shifamed portfolio company based in Campbell, CA that develops valve replacement solutions for mitral and tricuspid applications. Its core product is a transcatheter valve replacement technology designed to be procedurally simple and less invasive. The company is led by President and CEO Mike Dineen. Tioga raised $30M in a Series B financing led by The Capital Partnership, with participation from Cormorant Asset Management, AMED Ventures and Shifamed angel investors. The company intends to use the funds to advance product development, support pre-clinical testing and initiate clinical experience. The financing is intended to move the transcatheter valve replacement technology closer to clinical use. Tioga Medical is a Campbell, Calif.-based newly formed company developing a novel transcatheter valve replacement technology for mitral and tricuspid applications. Its core product is a less invasive, transcatheter approach intended to provide valve replacement solutions that are procedurally simple. The company’s initial focus is mitral valve disease, which the article notes is the largest structural heart valve problem and roughly four times more common than aortic stenosis. Tioga intends to use the Series A proceeds to advance its pre-clinical and clinical development programs. The company is a privately held portfolio company of Shifamed LLC and is led by President and CEO Mike Dineen. Shifamed, founded by serial entrepreneur Amr Salahieh, is described as a medical innovation hub focused on accelerating time to market, reducing risk, and increasing impact.

Total raised

$75M

Funding rounds

3

Latest round

Series C

Latest activity

Feb 2023